Scottish Brain Sciences

Scottish Brain Sciences occupies a specialised position at the intersection of neuroscience research, clinical-trial operations and diagnostic testing. Its differentiation is the integration of dedicated brain health research centres, in-house blood and cerebrospinal-fluid testing, imaging capabilities and a growing biobank combining genetic, blood and imaging data. That model contrasts with organisations focused on only one layer of the neurodegenerative-disease workflow, such as standalone contract research providers, diagnostic laboratories or digital cognitive-testing companies. The company’s focus on Alzheimer’s disease and earlier detection gives it a clear clinical domain, while its Aberdeen and Edinburgh facilities provide a physical infrastructure for participant recruitment, longitudinal assessment and biomarker work. Its collaboration with Roche, announced on Jun 1, 2026, adds access to an established blood-based biomarker test. Scottish Brain Sciences should therefore be viewed as a focused specialist platform rather than a demonstrably scaled category leader. Its competitive strength is the combination of research delivery and laboratory capability, while its main observable limitation is the lack of publicly quantified scale and funding history.

Scottish Brain Sciences shows a trajectory from a research-focused organisation founded in 2022 toward a broader clinical and laboratory platform. The first visible inflection point was its role as ONE BioHub’s anchor tenant in July 2024, followed by the opening of a new Aberdeen Alzheimer’s research centre on Nov 14, 2025. That expansion established a third research facility in Scotland and increased the organisation’s capacity for participant-facing studies. A second inflection point came in February 2026 with the appointment of Lewis Penny as Director of Laboratory Sciences, signalling investment in laboratory operations and scientific management. On Jun 1, 2026, the Edinburgh laboratory launch added accredited blood-based biomarker and cerebrospinal-fluid testing, while the Roche collaboration broadened the service’s clinical relevance. The company is consequently moving toward an integrated model linking recruitment, cognitive monitoring, imaging, biobanking and biomarker diagnostics. Its employee band is listed at 51–100, but only one current leadership position is detailed publicly, so headcount growth cannot be quantified. No funding rounds or amounts are publicly identified, leaving the capital intensity and sustainability of this expansion unclear.